SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-20-000125
Filing Date
2020-11-06
Accepted
2020-11-06 07:11:40
Documents
16
Period of Report
2020-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20201106.htm   iXBRL 8-K 39834
2 EX-99.1 jnce09302020exhibit991.htm EX-99.1 68431
8 jounceheader1.jpg GRAPHIC 45197
  Complete submission text file 0001640455-20-000125.txt   325858

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20201106.xsd EX-101.SCH 2424
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT jnce-20201106_cal.xml EX-101.CAL 714
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT jnce-20201106_def.xml EX-101.DEF 1651
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20201106_lab.xml EX-101.LAB 24975
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20201106_pre.xml EX-101.PRE 13191
9 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20201106_htm.xml XML 11205
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 201292373
SIC: 2836 Biological Products, (No Diagnostic Substances)